References
1. Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, Middeldorp S, et al. ESHRE guideline: recurrent pregnancy loss. Human reproduction open. 2018;2018(2):hoy004.
2. Li J, Gu Y, Zhang S, Ju B, Wang J. Effect of Prepregnancy Lymphocyte Active Immunotherapy on Unexplained Recurrent Miscarriage, Pregnancy Success Rate, and Maternal-Infant Outcome. BioMed research international. 2021;2021:7878752.
3. La X, Wang W, Zhang M, Liang L. Definition and Multiple Factors of Recurrent Spontaneous Abortion. Advances in experimental medicine and biology. 2021;1300:231-57.
4. Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent pregnancy loss. Nature reviews Disease primers. 2020;6(1):98.
5. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Journal of thrombosis and haemostasis : JTH. 2003;1(7):1566-74.
6. Sillen M, Declerck PJ. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. International journal of molecular sciences. 2021;22(7).
7. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. The Journal of biological chemistry. 2004;279(14):13333-9.
8. Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. Journal of thrombosis and haemostasis : JTH. 2012;10(11):2354-60.
9. Plug T, Meijers JC. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. Journal of thrombosis and haemostasis : JTH. 2016;14(4):633-44.
10. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nature medicine. 2003;9(3):331-7.
11. Legnani C, Bovara M, Valdrè L, Cosmi B, Caniato A, Palareti G. Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. Thrombosis research. 2012;130(2):237-41.
12. Folkeringa N, Korteweg FJ, Veeger NJ, Middeldorp S, Hamulyak K, Prins MH, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study. Thrombosis research. 2009;123(3):511-4.
13. Yildirim MN, Selcoki Y, Uysal S, Nacar AB, Demircelik B, Aydin HI, et al. Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow. Herz. 2014;39(8):993-1000.
14. He H, Jing S, Gong F, Tan YQ, Lu GX, Lin G. Effect of thyroid autoimmunity per se on assisted reproduction treatment outcomes: A meta-analysis. Taiwanese journal of obstetrics & gynecology. 2016;55(2):159-65.
15. Dhillon-Smith RK, Coomarasamy A. TPO antibody positivity and adverse pregnancy outcomes. Best practice & research Clinical endocrinology & metabolism. 2020;34(4):101433.
16. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid : official journal of the American Thyroid Association. 2017;27(3):315-89.
17. Iravani AT, Saeedi MM, Pakravesh J, Hamidi S, Abbasi M. Thyroid autoimmunity and recurrent spontaneous abortion in Iran: a case-control study. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2008;14(4):458-64.
18. Hooper JM, Stuijver DJ, Orme SM, van Zaane B, Hess K, Gerdes VE, et al. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. The Journal of clinical endocrinology and metabolism. 2012;97(5):1463-73.
19. Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? Journal of thrombosis and haemostasis : JTH. 2010;8(5):868-76.
20. Naito M, Taguchi O, Kobayashi T, Takagi T, D’Alessandro-Gabazza CN, Matsushima Y, et al. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system. American journal of respiratory cell and molecular biology. 2013;49(4):646-53.
21. Yoshida K, Takabayashi T, Imoto Y, Sakashita M, Kato Y, Narita N, et al. Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis. The Laryngoscope. 2021;131(11):2413-20.
22. Mook-Kanamori BB, Valls Serón M, Geldhoff M, Havik SR, van der Ende A, Baas F, et al. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. Journal of thrombosis and haemostasis : JTH. 2015;13(11):2076-86.
23. Chen L, Hu R. Thyroid autoimmunity and miscarriage: a meta-analysis. Clinical endocrinology. 2011;74(4):513-9.
24. Chardès T, Chapal N, Bresson D, Bès C, Giudicelli V, Lefranc MP, et al. The human anti-thyroid peroxidase autoantibody repertoire in Graves’ and Hashimoto’s autoimmune thyroid diseases. Immunogenetics. 2002;54(3):141-57.
25. Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the Pregnant Woman, the Placenta, the Fetus, and the Newborn Infant. Seminars in thrombosis and hemostasis. 2023;49(4):319-29.
26. Knol HM, Veeger NJ, Middeldorp S, Hamulyák K, Van Der Meer J. High thrombin-activatable fibrinolysis inhibitor levels may protect against recurrent fetal loss. Journal of thrombosis and haemostasis : JTH. 2009;7(5):903-6.
27. Masini S, Ticconi C, Gravina P, Tomassini M, Pietropolli A, Forte V, et al. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss. Fertil Steril. 2009;92(2):694-702.
28. Eser A, Inegol Gumus I, Erdamar H, Kaygusuz I, Yildirim M, Usluogullari B, et al. Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients. Taiwanese journal of obstetrics & gynecology. 2016;55(1):60-3.
29. Martínez-Zamora MA, Creus M, Tassies D, Bové A, Reverter JC, Carmona F, et al. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome. Fertil Steril. 2010;94(6):2437-40.
30. Schroeder V, Wilmer M, Buehler B, Kohler HP. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thrombosis and haemostasis. 2006;96(2):236-7.
31. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clinical biochemistry. 2007;40(7):431-42.
32. Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). Thrombosis research. 2017;158:168-73.
33. Ermantas N, Guldiken S, Demir M, Tugrul A. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2010;16(5):568-73.
34. Ellervik C, Mora S, Kuś A, Åsvold B, Marouli E, Deloukas P, et al. Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study. Thyroid : official journal of the American Thyroid Association. 2021;31(9):1305-15.